Cibus, INC 8-K filings

Cibus, Inc. announced its second quarter financial results, showcasing advancements in its Rice and Sustainable Ingredients programs, favorable regulatory developments in the EU and US, and a sequential decrease in net cash usage.

Cibus, Inc. announced leadership changes with Craig Wichner appointed as CEO, succeeding Peter Beetham who returns to President and COO role, as part of a succession plan.

Cibus, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of nine directors and the ratification of its independent auditor.

Cibus, Inc. announced its first quarter 2026 financial results, highlighting progress in its Rice herbicide tolerance and Sustainable Ingredients programs, alongside positive regulatory developments and a strengthened balance sheet.

Cibus, Inc. announced the appointment of Thomas Urban to its Board of Directors, effective April 7, 2026, bringing extensive agribusiness and finance experience.

Cibus, Inc. announced an underwritten public offering of 6.98 million shares of Class A common stock at $2.15 per share, aiming to raise approximately $13.5 million in net proceeds.

Cibus, Inc. announced its Q4 and full-year 2025 financial results, highlighting significant progress in gene-editing technology and commercialization efforts for its plant traits.

Cibus, Inc. announced an underwritten public offering of 13,333,333 shares of Class A common stock at $1.50 per share, aiming to raise approximately $17.8 million in net proceeds.

Cibus, Inc. announced updated business disclosures in connection with an underwritten offering, emphasizing its Rice herbicide tolerance traits and streamlining operations.

Cibus, Inc. announced the repurchase of 60,088 shares of its Class A common stock from an employee at a nominal price.

Cibus, Inc. announced its third quarter 2025 financial results, highlighting expanded Latin American rice partnerships, positive field trial outcomes, and significant cost reduction initiatives.

Cibus, Inc. announced the appointment of Craig Wichner, founder of Farmland LP, to its Board of Directors and Strategy Committee, effective November 5, 2025.

Cibus, Inc. has officially appointed Cornelis (Carlo) Broos as its Chief Financial Officer, effective September 18, 2025, after serving as interim CFO.

Cibus, Inc. announced the appointment of Kimberly A. Box, a seasoned executive with extensive experience in technology and healthcare, to its Board of Directors, effective September 11, 2025.

Cibus, Inc. reported a reduced net loss in the second quarter of 2025, driven by cost-cutting and a strategic focus on Rice herbicide tolerance traits and partner-funded programs, extending its cash runway into Q2 2026.

Cibus, Inc. approved a reduction of approximately 34 full-time employees, incurring an estimated $0.5 million in one-time charges, as part of its strategic business focus.

Cibus, Inc. announced the closing of a public offering raising approximately $27.5 million in gross proceeds, with funds earmarked for the development of weed management traits in Rice and general corporate purposes.

Cibus, Inc. announced a strategic streamlining of its business focus to prioritize its Rice weed management traits and partner-funded programs, aiming to reduce annual net cash burn to $30 million by 2026, while highlighting significant positive global regulatory developments for gene-edited crops.

Cibus, Inc. announced that its stockholders have approved the 2025 Employee Stock Purchase Plan, enabling employees to acquire company stock through payroll deductions and reserving an initial 326,384 shares with potential for significant annual increases.

Cibus, Inc. announced that its stockholders approved all seven proposals at the 2025 Annual Meeting, including the election of directors, executive compensation, auditor ratification, a new employee stock purchase plan, and the authorization of significant warrant-related share issuances.

Cibus Inc. announced its Q1 2025 financial results, highlighting progress in rice and canola trait development, regulatory advancements, and ongoing efforts to secure additional funding.

Cibus, Inc. amended its previous 8-K filing to report an increase in the base salary of Interim CEO Dr. Peter Beetham.

Cibus, Inc. announced its Q4 2024 financial results and provided a business update, emphasizing advancements in its gene editing technologies and commercialization efforts.

Cibus, Inc. announces that Rory Riggs has resigned as CEO and Peter Beetham has been appointed as Interim CEO as part of the company's succession planning strategy.

Cibus Inc. enters into securities purchase agreements for a registered direct offering of shares, warrants, and pre-funded warrants, aiming to raise $10.85 million.

Cibus Inc.'s Compensation Committee has approved a $320,000 base salary for Mr. Carlo Broos, effective December 3, 2024.

Cibus Inc. has appointed August Moretti, a seasoned financial executive, to its Board of Directors and Audit Committee, effective November 18, 2024.

Cibus reports third quarter financial results, announces a strategic realignment to focus on key commercial opportunities, and details progress in its gene editing technology.

Cibus Inc. released an updated corporate presentation detailing its trait licensing business model, technology, and pipeline of gene-edited agricultural traits.

Cibus Inc. is implementing a strategic realignment that includes a workforce reduction of approximately 26 employees and other cost-cutting measures.